The United States, already grappling with an escalating opioid crisis, now faces a new threat that could worsen this public health emergency: significant cuts to Medicaid coverage and addiction treatment programs under President Trump’s newly passed “Big Beautiful Bill.” Public health researchers are sounding urgent alarms about the potential consequences it will have for America’s ongoing battle against the opioid epidemic. 

Medicaid’s Role in Fighting the Opioid Crisis

Since the Affordable Care Act’s Medicaid expansion in 2014, millions of Americans have gained access to addiction treatment services, from medication-assisted treatment (MAT) to counseling and recovery programs. Medicaid became the largest single payer for substance use disorder treatment in the U.S., covering about 40% of all nonelderly adults with opioid addiction. But the “Big Beautiful Bill” shifts Medicaid from an open-ended entitlement to a capped block grant program, giving states a fixed sum each year, regardless of rising need. Critics say that in states hit hardest by the opioid epidemic, these limits will force deep cuts in coverage, with addiction treatment often the first to go. Already, overdose deaths in the U.S. have reached record highs, over 100,000 in 2023, according to the CDC. Advocates warn that slashing treatment access at this moment could accelerate the death toll.

The Research Behind the Warnings

Researchers affiliated with the Center for Health Economics of Treatment Interventions for Substance Use Disorder delivered their analysis to House Speaker Mike Johnson and Majority Leader John Thune in July. The team used sophisticated modeling to project the real-world consequences of Medicaid cuts now being implemented across states.

The Congressional Budget Office estimates that 7.8 million people will lose Medicaid coverage under the new law. Building on federal data showing that roughly 2% of Medicaid enrollees receive medications for opioid use disorder, researchers calculated that 156,000 people with addiction will lose treatment access.

Using the RESPOND population-based model, the analysis projects that overdose rates among those losing treatment will double in the first year following coverage loss. This finding aligns with clinical research showing that cessation of medication-based treatment leads to a six-fold higher risk of death in the four weeks immediately following treatment disruption.

The Progress being Undone

The timing of the Medicaid cuts coincides with remarkable progress in reducing overdose deaths. CDC provisional data shows a 26.9% decrease in drug overdose deaths in 2024, falling from 110,037 deaths in 2023 to an estimated 80,391 deaths. "This decline represents more than 81 lives saved every day compared to 2023 levels," CDC officials said in their analysis of the 2024 data. The question facing public health officials is whether the enacted budget changes will reverse this unprecedented progress.

Geographic Impact Varies

The impact of Medicaid cuts will not be distributed evenly across communities. States that expanded Medicaid under the Affordable Care Act now face the most severe disruptions to their treatment infrastructure. Rural communities present particularly concerning scenarios. These areas already struggle with provider shortages, limited treatment facilities, and transportation barriers that complicate access to care. States like West Virginia, Ohio, and Kentucky, which have among the nation's highest rates of opioid-related mortality, are now forcing officials to choose between maintaining treatment programs and addressing other health priorities.

Urban safety-net hospitals and community health centers serving large Medicaid populations face significant financial strain, which may lead to service reductions or facility closures.

Looking Forward

The study forecasting that 156,000 Americans will be cut off from life-saving addiction treatment is more than an academic exercise. These forecasts reflect a nascent reality that individuals, families, and communities, in the wake of implementing the new law, will be confronting as states deal with the evident tension between the fiscal imperatives of the new law and the public health implications. The evidence overwhelmingly suggests that eliminating Medicaid coverage for addiction treatment will cost lives in the long run, while also leading to larger, longer-term costs in multiple other systems. The important question now is whether America will be able to find a way to mitigate the damage to its advances in responding to the opioid epidemic, or whether the policies implemented therein will mark a substantial reversal on the opioid epidemic that has severe consequences for those most vulnerable. There's a lot to lose as America tries to manage the implications of statutory changes that could potentially undo one of the most significant accomplishments for public health in recent times.